Arbutus Biopharma (ABUS) Misses Q4 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ABUS Hot Sheet
Join SI Premium – FREE
Arbutus Biopharma (NASDAQ: ABUS) reported Q4 EPS of ($0.17), $0.14 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $14.08 million versus the consensus estimate of $776.33 thousand.
For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- William Blair Downgrades Fidelity National Information Services (FIS) to Market Perform
- AppLovin stock setup into today's earnings: Here's what analysts say
- SEC Adopts Amendments to Update Definitions of Small Entity for Investment Companies and Investment Advisers
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
